PMID

Data

Article Title

Organization

Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding Group.

Merck Research Laboratories

OpenGrowth: An Automated and Rational Algorithm for Finding New Protein Ligands.

Harvard University

De Novo Design at the Edge of Chaos.

Swiss Federal Institute of Technology (Eth)

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

Shandong University

Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir.

Philipps-Universit£T Marburg

Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.

Peking Union Medical College

An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.

University of Michigan

Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.

University of Florence

Impact of Stereochemistry on Ligand Binding: X-ray Crystallographic Analysis of an Epoxide-Based HIV Protease Inhibitor.

University of Trieste

Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.

Kyoto Pharmaceutical University

Structural Analysis of Potent Hybrid HIV-1 Protease Inhibitors Containing Bis-tetrahydrofuran in a Pseudosymmetric Dipeptide Isostere.

University of Massachusetts Medical School

Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.

Purdue University

Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.

Purdue University

Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry.

Purdue University

Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir.

TBA

Potent HIV-1 protease inhibitors incorporating squaramide-derived P2 ligands: Design, synthesis, and biological evaluation.

Purdue University

Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors incorporating aminothiochromane and aminotetrahydronaphthalene carboxamide derivatives as the P2 ligands.

Purdue University

Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.

Peking Union Medical College

Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.

Peking Union Medical College

Oleanolic Acid Derivatives as Potential Inhibitors of HIV-1 Protease.

TBA

Overview of Recent Strategic Advances in Medicinal Chemistry.

Shandong University

Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants.

Peking Union Medical College

HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.

University of Massachusetts Medical School

Synthetic, structural mimetics of the β-hairpin flap of HIV-1 protease inhibit enzyme function.

University of Maryland

Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.

Purdue University

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods.

Nankai University

Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.

Purdue University

Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studies.

Purdue University

Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.

Georgia State University

Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.

Shandong University

Effect of prime-site sequence of retro-inverso-modified HTLV-1 protease inhibitor.

Kyoto Prefectural University of Medicine

Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.

Universidad De Granada

Modular construction of quaternary hemiaminal-based inhibitor candidates and their in cellulo assessment with HIV-1 protease.

University of Lyon

Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.

Wayne State University

Design and synthesis of P1-P3 macrocyclic tertiary-alcohol-comprising HIV-1 protease inhibitors.

Uppsala University

Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

Purdue University

Dissecting the pharmacophore of curcumin. Which structural element is critical for which action?

University of Eastern Piedmont

Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors.

Rhodes University

Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.

Georgia State University

Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.

Academy of Sciences of The Czech Republic

Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.

Paris-Sud University

Design, synthesis, and biological and structural evaluations of novel HIV-1 protease inhibitors to combat drug resistance.

Sanford-Burnham Medical Research Institute

Rational approaches to improving selectivity in drug design.

University of Cambridge

Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.

Universidad De Santiago De Compostela

Synthesis and biological activity of potent HIV-1 protease inhibitors based on Phe-Pro dihydroxyethylene isosteres.

University of Trieste

Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.

Georgia State University

Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors.

University of Southampton

Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease.

University of Kwazulu-Natal

Synthesis, X-ray analysis, and biological evaluation of a new class of stereopure lactam-based HIV-1 protease inhibitors.

Uppsala University

Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.

University of Basilicata

Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

Purdue University

Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.

Chinese Academy of Sciences

Design, synthesis, and X-ray crystallographic analysis of a novel class of HIV-1 protease inhibitors.

Stevens Institute of Technology

Design of HIV-1 protease inhibitors with C3-substituted hexahydrocyclopentafuranyl urethanes as P2-ligands: synthesis, biological evaluation, and protein-ligand X-ray crystal structure.

Purdue University

Novel 3alpha-methoxyserrat-14-en-21beta-ol (PJ-1) and 3beta-methoxyserrat-14-en-21beta-ol (PJ-2)-curcumin, kojic acid, quercetin, and baicalein conjugates as HIV agents.

Osaka University of Pharmaceutical Sciences

Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.

University of Kwazulu-Natal

Design and synthesis of several small-size HTLV-I protease inhibitors with different hydrophilicity profiles.

Kyoto Pharmaceutical University

Maintaining potent HTLV-I protease inhibition without the P3-cap moiety in small tetrapeptidic inhibitors.

Kyoto Pharmaceutical University

Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluation.

Purdue University

Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones.

University of Massachusetts Medical School

Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.

Jadavpur University

Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.

Beijing Institute of Biotechnology

Epsilon substituted lysinol derivatives as HIV-1 protease inhibitors.

Merck Research Laboratories

Inhibition of the dimerization and active site of HIV-1 protease by secondary metabolites from the Vietnamese mushroom Ganoderma colossum.

University of Toyama

Synthesis and biological evaluation of novel allophenylnorstatine-based HIV-1 protease inhibitors incorporating high affinity P2-ligands.

Purdue University

Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.

University of Minnesota

Synthesis of new thienyl ring containing HIV-1 protease inhibitors: promising preliminary pharmacological evaluation against recombinant HIV-1 proteases.

University of Basilicata

3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.

Universidade Federal De Lavras

Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates.

Uppsala University

HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.

Uppsala University

Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.

Kyoto Pharmaceutical University

Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.

Stockholm University

Evaluation of triazolamers as active site inhibitors of HIV-1 protease.

New York University

Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.

National Cancer Institute

On the inhibition of HIV-1 protease by hydrazino-ureas displaying the N-->C=O interaction.

University of Lyon

In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.

Glaxosmithkline

Synthesis of dammarane-type triterpene derivatives and their ability to inhibit HIV and HCV proteases.

University of Toyama

Sidechain-linked inhibitors of HIV-1 protease dimerization.

Purdue University

A copper(I)-catalyzed 1,2,3-triazole azide-alkyne click compound is a potent inhibitor of a multidrug-resistant HIV-1 protease variant.

The Scripps Research Institute

Solution kinetics measurements suggest HIV-1 protease has two binding sites for darunavir and amprenavir.

Georgia State University

Anti-HIV-1 activity of phloroglucinol derivative, 6,6'-bieckol, from Ecklonia cava.

Pukyong National University

Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.

University of Minnesota

Anti-HIV-1 protease activity of lanostane triterpenes from the vietnamese mushroom Ganoderma colossum.

University of Toyama

Microbial transformation of L-696,474, a novel cytochalasin as an inhibitor of HIV-1 protease.

Merck Research Laboratories

In silico screening of HIV-1 non-nucleoside reverse transcriptase and protease inhibitors.

Universidade Federal De Minas Gerais

Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.

Academy of Sciences of The Czech Republic

Is quantum mechanics necessary for predicting binding free energy?

University of Z£Rich

Locking the two ends of tetrapeptidic HTLV-I protease inhibitors inside the enzyme.

Kyoto Pharmaceutical University

Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia.

Toyama Medical and Pharmaceutical University

Guaiane dimers and germacranolide from Artemisia caruifolia.

Toyama Medical and Pharmaceutical University

Anti-HIV-1 protease triterpenoid saponins from the seeds of Aesculus chinensis.

Beijing Medical University

Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.

Kyoto Pharmaceutical University

Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization.

Kumamoto University Graduate School of Medical and Pharmaceutical Sciences

Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.

Philipps-Universit£T Marburg

Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.

Dainippon Sumitomo Pharma

Two-carbon-elongated HIV-1 protease inhibitors with a tertiary-alcohol-containing transition-state mimic.

Uppsala University

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Purdue University

A review of anti-infective and anti-inflammatory chalcones.

Adam Mickiewicz University

Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.

Merck Research Laboratories

Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.

University of Minnesota

Brominated polyacetylenic acids from the marine sponge Xestospongia muta: inhibitors of HIV protease.

Smithkline Beecham Pharmaceuticals

Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Georgia State University

Isolation and synthesis of a new bioactive ellagic acid derivative from Combretum yunnanensis.

Teikyo University

Design and Synthesis of Potent HIV-1 Protease Inhibitors Containing Bicyclic Oxazolidinone Scaffold as the P2 Ligands: Structure-Activity Studies and Biological and X-ray Structural Studies.

Purdue University

Druggability Assessment of Targets Used in Kinetic Target-Guided Synthesis.

University of Groningen

Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.

Purdue University

Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir.

TBA

Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 Tetrahydrofuranylglycine.

Kobe Gakuin University

Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease Inhibitors.

Merck

Design and synthesis of selenazole-substituted ritonavir analogs.

Chinese Academy of Science

Design and synthesis of potent HIV-1 protease inhibitors with (S)-tetrahydrofuran-tertiary amine-acetamide as P2-ligand: Structure-activity studies and biological evaluation.

Peking Union Medical College

Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.

Gliatech